Total Credits: 7.75 including 7.75 AOA Category 1-A Credit(s)
- Average Rating:
- 4
- Faculty:
- Carolynn Francavilla, MD | Dodson Thompson, D.O. | Lindsey Van Duyn, DO | Sara Spiva, DO | Brandi Stalzer, LIMHP, LPCC, LMHC, BC-TMH | Kevin Miller, DO | Yogesh Shah, M.D., MPH, FAAFP
- Short Description:
- This is the metabolic health package of conference recordings from the 2025 Upper Midwest Osteopathic Health Conference, "Breaking Barriers in Digestive and Metabolic Health." There are 2 other packages of these courses, one with just the courses from the emergency medicine track and one with all the courses from the entire conference. All of the sessions in this package are available for individual purchase as well.
- Price:
- $275.00 - Base Price
Total Credits: 23.75 including 23.75 AOA Category 1-A Credit(s)
- Average Rating:
- Not yet rated
- Faculty:
- Carolynn Francavilla, MD | Dodson Thompson, D.O. | Lindsey Van Duyn, DO | Sara Spiva, DO | Brandi Stalzer, LIMHP, LPCC, LMHC, BC-TMH | Yogesh Shah, M.D., MPH, FAAFP | Kevin Miller, DO | Tami Lyday, DO | ....
- Short Description:
- This is the full package of all conference recordings from the 2025 Upper Midwest Osteopathic Health Conference, "Breaking Barriers in Digestive and Metabolic Health." There are 2 other packages of these courses, one with just the metabolic health courses and one with just the courses from the emergency medicine track. All of the sessions in this package are available for individual purchase as well.
- Price:
- $775.00 - Base Price
Total Credits: 1 including 1 AOA Category 1-A Credit(s)
- Average Rating:
- 19
- Faculty:
- Hilary Lois, DO
- Short Description:
- The American Association for the Study of Liver Disease (AASLD) states that MASLD affects over 30% of the global population and is now the primary cause of chronic liver disease. Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major driver of hepatic disease and is associated with numerous conditions seen in primary care, such as prediabetes, type 2 diabetes, obesity, atherosclerosis, and dyslipidemia. Hepatic disease associated with MASLD exists on a spectrum and can progress to liver fibrosis, cirrhosis, and even hepatocellular carcinoma. Nomenclature of this condition, previously known as non-alcoholic fatty liver disease (NAFLD), has recently been revised. This presentation will review the updated terminology, as well as review guidelines and recommendations that exist to help with screening, identification, monitoring, referral indications, and treatment of this disease.
- Price:
- $40.00 - Base Price